Professionals working in the pharma, medical device, and biotechnology companies, are invited to attend the DGE event, Incorporate Patient Voice Across the Commercial Product Lifecycle being held in Philadelphia on January 25-26, 2024. A live-streaming option for the event is also available.

The event is organized by Dynamic Global Events (“DGE”), a leading life science B2B event organizing company. DGE provides dynamic informational and networking support to the pharmaceutical, biotechnology, healthcare, and medical devices verticals.

This program will educate professionals working in patient engagement and experience and commercial teams on how to access patient insights and incorporate into product launches and patient support services.

Topics of discussion include:

• Learn the current innovations in patient engagement
• Understand and validate patient feedback
• Get case studies for turning patient insights into actionable data
• Put patients at the center of market access, evidence and value based strategy
• Design better initiatives for disease awareness and patient education

Industry experts and top executives attending the event will discuss the key takeaways, that include offering end-to-end support for patients in several areas, namely disease awareness, patient education, and marketing. With better patient insights being incorporated into product lifecycles, patients will receive better care. The event offers a great forum to connect with life science advocates and leaders.

To know more, please visit https://ibn.fm/3jfCh.

GolfLync, the pioneering golf social networking platform, is revolutionizing golf networking. GolfLync’s focus is on connecting like-minded players over their shared love for golf. New advanced filtering algorithms empower users to match with new players, find local friends, and discover new Virtual Golf Clubs (“VGC”) locally and while traveling. Now finding the perfect match is easier than ever!

Discovery Features: GolfLync’s discovery features allow members to set up filters for viewing content and connecting with members, whether on a local or national level. Easily find and engage with like-minded golfers.

Influencer Badges: GolfLync now offers influencer badges, earned by submitting government-issued IDs and undergoing validation, ensuring authenticity and trust.

Enhanced Reporting: Advanced screening tools allow users to filter, block, and report any spam, preserving the platform’s authenticity.

Verification Application: An in-app verification application enables users to apply for verified status, enhancing trust and recognition within the golfing community.

About GolfLync
GolfLync is the ultimate social media platform for golfers, connecting like-minded enthusiasts, fostering vibrant golfing communities, and redefining the golfing experience. With a user-friendly interface and advanced features, GolfLync brings golfers together and provides a space for golfers to connect, share, and celebrate their shared passion.

For more information about GolfLync and the groundbreaking initiatives that are transforming the golfing landscape, visit GolfLync and be part of a revolution in golfing camaraderie.

Available for free from both the Apple Store and Google Play stores. Create your account today and join in on the fun!

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• Lexaria, a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing GLP-1 human pilot study
• The study seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide
• Lexaria’s DehydraTECH GLP-1 showed a 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group
• The DehydraTECH GLP-1 group also only saw a 5.3% spike in glucose levels after having a standardized meal at the 240-minute mark and a snack at the 360-minute mark, compared to 22.7% for the control group

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced additional positive interim results from its ongoing human pilot study that seeks to provide an early-stage indication of whether DehydraTECH(TM) processing could improve oral drug delivery characteristics of the GLP-1 drug semaglutide. The study, which focused on Rybelsus(R), a commercially available semaglutide drug, involved seven healthy subjects, four of whom received the DehydraTECH GLP-1, with the other three receiving the control (https://ibn.fm/2BPlK).

Of note was DehydraTECH GLP-1’s 2.9% to 14.6% blood glucose level reduction relative to baseline, compared to 1.3% to 6.7% for the control group. These results were achieved in the initial 100 minutes of taking the drugs, and at all but the 20-minute and 240-minute sample time points, the DehydraTECH GLP-1 blood glucose levels were reduced more than evidenced by the control group. More so, even 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline. In contrast, that of the control group was only reduced by 0.67%. This evidenced a nearly ten-fold improvement with DehydraTECH GLP-1.

When the subjects were permitted to eat a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark, glucose levels spiked by 22.7% for the control group, while those in the DehydraTECH GLP-1 group only saw a 5.3% rise. Although this cannot be attributed to DehydraTECH GLP-1’s overall efficacy in achieving sustained blood glucose reduction, it is a plausible explanation for the difference and a pointer to the overall potential of the technology.

While there are still some additional steps to be taken, these positive results are welcome and point to the technology’s potential, specifically in diabetes treatment. In the DIAB-A22-1 animal study, Lexaria demonstrated at least three positive outcomes, which included weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels. The study also demonstrated an improvement in locomotor activity compared to untreated obese control rats, with no severe health concerns during dosing (https://ibn.fm/Bei48).

With the results from Lexaria’s DehydraTECH GLP-1, the company is on track to replicate the positive results from its diabetes study. More importantly, it is on track to carve out a decent market share in an industry projected to bring between $150 billion and $200 billion a year (https://ibn.fm/X03Wa). By doing so, it will also ensure that GLP-1 drugs are more effective with reduced side effects while also being accessible to individuals living with diabetes. It also hopes it will improve the quality of life of people living with the condition by offering a less intrusive and less painful treatment alternative than what is currently in the market.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million
• The company intends to use the proceeds to pay an outstanding promissory note, advance development programs, and general corporate purposes
• PaxMedica received constructive feedback from its type-B meeting with the FDA, which will aid in completing the remaining paperwork necessary to file a New Drug Application
• The company is currently working on commercial lots of PAX-101, which are expected during the first half of 2024, for the New Drug Application, which is expected to be filed during the second half of 2024

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently reported the closing of its public offering. PaxMedica’s total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, were approximately $7 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering (https://ibn.fm/XEIiL).

The previously announced public offering is an aggregate of 5,384,615 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,384,615 shares of common stock at a public offering price of $1.30 per share and accompanying warrant. The warrants have an exercise price of $1.30 per share and are exercisable immediately upon issuance – with an expiration of five years from the initial exercise date.

The company intends to use the net proceeds from this offering to repay an outstanding $0.2 million convertible promissory note held by Lind Global Fund II LP to advance PaxMedica’s development programs and for general corporate purposes.

Part of PaxMedica’s pipeline includes using suramin sodium in Stage One Human African Sleeping Sickness, which will help further the company’s efforts to develop therapies for ASD and other neurological symptoms. PaxMedica recently completed a type-B meeting with the FDA regarding the positive data results from its PAX-HAT-301 study.

The PAX-HAT-301 study is a retrospective, non-randomized, externally controlled, interventional efficacy and safety study comparing medical records data from a cohort of patients with Stage 1 Trypanosoma Brucei Rhodesiense (African Sleeping Sickness). These patients were treated from about 2000 to 2020 at a medical site in Uganda and two medical sites in Malawi. Medical records data from a cohort of patients from 1900 to 1910 from the TBR HAT epidemic in Uganda were also evaluated. The study aimed to determine if the treatments with suramin sodium from 2000 to 2020 were more effective at treating the disease than the outcomes observed in the epidemic over 100 years ago.

PaxMedica received constructive feedback, which will aid in completing the remaining paperwork necessary to file a New Drug Application (“NDA”), expected in the second half of 2024. Most of the work to achieve this milestone will focus on completing the production of commercial lots of PAX-101 under CMC regulatory guidelines, which are underway now and expected to conclude in the first half of 2024.

“This is an important turning point for our young company, and we are very pleased with the guidance that the FDA has provided us in this meeting,” said Howard Weisman, CEO and Chairman of PaxMedica (https://ibn.fm/CjaxD). “We look forward to urgently completing the necessary steps in the coming months to clear the path to submit our first NDA for PAX-101.”

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• D-Wave recently shared important research results demonstrating successful quantum error mitigation (“QEM”) in its Advantage2(TM) annealing quantum computing experimental prototype
• The company’s latest research focuses on zero-noise extrapolation, one of the most practical QEM techniques, maintaining the quantum state and reducing errors
• D-Wave has also made significant progress with high-coherence fluxonium qubits, setting new standards in quantum properties

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently shared important research results that demonstrate successful quantum error mitigation (“QEM”) in its Advantage2(TM) annealing quantum computing experimental prototype. This progress in reducing errors in quantum computers is expected to drive performance advancements in the company’s future quantum computing systems and processors.

Quantum computing is incredibly powerful but can be sensitive to noise and imperfections in the hardware – known as “errors.” Fixing these errors is a major challenge, and while there is a solution called quantum error correction, it’s currently too complex and resource-intensive to be practical. Instead, D-Wave has applied QEM as a near-term solution to estimate error-free expectation values in the presence of small noise.

D-Wave’s latest research focuses on zero-noise extrapolation (“ZNE”), one of the most practical QEM techniques. These techniques, used in the company’s Advantage2 annealing quantum computing experimental prototype, showed reduced errors in quantum simulation and produced results consistent with the quantum system maintaining its quantum state (known as “coherence”) for a much longer period of time compared to when no mitigation techniques are applied. This means better and more reliable results.

This breakthrough could translate to higher performance for D-Wave’s future quantum computers, like the upcoming Advantage2 system. Applying these research findings, D-Wave’s quantum systems and processors are expected to be able to tackle highly computationally complex problems in scientific-related and machine learning applications.

Mohammad Amin, a key researcher at D-Wave, underlined that errors are the biggest challenge in quantum computing. “With this research, we’ve demonstrated the successful mitigation of such errors in quantum annealing, producing measurement results as if the qubits were nearly one order of magnitude more coherent,” Amin said (https://ibn.fm/BYALl). “This opens up new possibilities, like simulating exotic materials and moving closer to achieving quantum supremacy on D-Wave processors.”

This isn’t the first time D-Wave has pushed the boundaries of quantum computing. Most recently, in September 2023, the company announced significant progress with high-coherence fluxonium qubits, which demonstrated quantum properties that are comparable to the best seen to date in scientific literature.

These fluxonium qubits are a key part of the next-generation quantum computers. D-Wave is especially interested in using them, as they’ve displayed some advantages over other types of qubits. The tests showed that these fluxonium qubits can stay stable for over 100 microseconds, and the measured effective temperature of its fluxonium, 18 millikelvin, is among the best that has been reported in the scientific literature to date for superconducting qubits.

“This shows that fluxonium is a viable candidate qubit for D-Wave’s gate model quantum computing architectures,” said Mark Johnson, SVP of quantum technologies at D-Wave (https://ibn.fm/0OpRu). “Moreover, in doing this work we have learned that fluxonium can address some of the known shortcomings of competing superconducting gate model qubits. We believe this will have a significant impact on D-Wave’s hardware development, and it also reinforces our technical leadership.”

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential impact and results of D-Wave’s progress in QEM; the new possibilities that may result from successful QEM including simulating exotic materials and moving closer to quantum supremacy on D-Wave processors; the potential impact of D-Wave’s work with fluxonium qubits on D-Wave’s hardware development and technical leadership. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the possibility for research results to differ in the future from what has been recorded to date; general economic conditions and other risks; D-Wave’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against the company; risks related to the performance of D-Wave’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of D-Wave’s products; the effects of competition on the company’s business; the risk that the company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of its securities; the risk that D-Wave’s securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. D-Wave undertakes no duty to update this information unless required by law.

• Security tokens are becoming increasingly popular as minimized risk entry points for digital infrastructure markets, with smart algorithms beginning to effectively deal with redemption dispute resolution concerns
• Utah-based Diamond Lake Minerals recently shifted its focus from mining holdings to digital assets and security tokens offerings, and has seen its market interest rise in the process
• DLMI aims to build an industry-agnostic, vertically integrated holding company that helps its subsidiaries develop self-sufficiency while offering an inroad to experienced investors wary of digital asset involvement — functioning as a “generational wealth” bridge
• Some market insiders see tokenization as the launch of a new Golden Age in blockchain and traditional finance

As market traders increasingly adopt security tokens into their investment portfolios, a new period of market evolution is unfolding and multi-strategy operating company Diamond Lake Minerals (OTC: DLMI) is developing a reputation for helping customers participate in new tech-based opportunities without having to figure out the intricacies of buying crypto and other digital assets.

The company’s market capitalization has jumped from “around a million dollars” to over $138 million in just a few months, accompanied by a significant boost in stock price, since it announced a shift into the digital asset and security token space.

“I believe DLMI is the hybrid missing piece to get generational wealth, or the wealth on the sidelines,” CEO Brian J. Esposito said during a November Bell2Bell podcast interview (https://ibn.fm/TGCaG). “(Experienced investors’) kids are involved with (digital assets). They hear about it at work. … Maybe they don’t trust it, maybe they don’t understand it, or they’re insecure about it, they don’t know how to download a digital wallet. So what we’re building is the ability to be involved in that space, through a regulated environment.”

DLMI’s market strategy involves building a vertically integrated ecosystem of numerous industry-agnostic holdings and imbuing each with a U.S. Securities and Exchange Commission (“SEC”)-registered security token offering (“STO”) designed to appeal to traditional investors who are otherwise unfamiliar with digital assets.

DLMI is not just another security token or digital asset company. It is building traditional businesses across multiple industries, and those business subsidiaries owned by DLMI will have security token offerings and components. The company will be properly including subsidiaries in their business models and in a regulated environment with their regulated SEC security token exchange partner INX (see INX link below).

Tokenization involves the use of digital assets that can be traded via protocols, and STOs attempt to provide confidence in the ability to redeem tokenized assets with minimal third-party involvement and maximum transparency.

The strength of DLMI’s approach to delivering tokenized rights to assets that have real value such as share ownership in real estate, investment funds and artwork is its adherence to U.S. Securities and Exchange Commission (“SEC”) regulations.

Web3 technologies such as decentralized finance (“DeFi”) and non-fungible tokens (“NFTs”) have installed the technological infrastructure to enable a new financial system, and tokenization of real world assets (“RWAs”) is expected to herald a new Golden Age in blockchain as well as traditional finance by unlocking the transfer of trillions of dollars of value into crypto, according to crypto media outlet CoinDesk (https://ibn.fm/2jOjh).

“The next generation for markets, the next generation for securities, will be tokenization of securities,” world-leading asset manager BlackRock’s CEO Larry Fink told the outlet.

DLMI is starting, acquiring and building a wide variety of subsidiaries that will “share resources, support one another, and ensure that if there’s a downside in one industry or segment, that we have a diversified model to help keep everything afloat and everything growing,” Esposito said.  “I love working in the regulated environment because it’s a place that helps ensure protecting people.”

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• CEO and President Samuel David discussed the success of Prospera’s drilling program in recent interview, revealed positive results and cost reductions
• Prospera management estimates as little as 8% of over half a billion barrels across assets have been recovered using traditional vertical well technology
• Phase 2 of drilling program focused on transition from vertical to horizontal well drilling, allowing the company to tap into the significant remaining reserves
• Recent Q3 2023 financial highlights include Q/Q rise in operating income from $783,084 to $1,101,827 and positive net income of $71,011 compared to net loss of $779,438 in Q2 2023

Samuel David, President and CEO of Prospera Energy (TSX.V: PEI) (OTC:s GXRFF) (FRA: OF6B), recently discussed the company’s successful drilling program in an interview on the Financial Survival Network (https://ibn.fm/44mbK).

“We have drilled five horizontals and infield drilling based on geological well delineation, well control, and seismic delineation,” said Mr. David during the interview. “Therefore, the chance of success of geological, of finding the reservoir, is high. The only risk is mechanical because this is infill low-risk drilling. We tweaked it by drilling a couple of pilot wells prior to embarking on this development program.”

“These wells encountered pay structure and oil as we expected, and we came in under budget by about 15%. I think we can even tweak that a little bit more as we extend the drilling.”

Prospera recently transformed into a sustainable energy producer that focuses on efficient hydrocarbon development, recovery, and production practices. Assets include 42,000+ acres across Cuthbert, Luseland and Heart Hills in Saskatchewan, and Red Earth and Pouce Coupe in Alberta.

Company management estimates that roughly 8% of over half a billion available barrels have been recovered using traditional vertical well technology. Phase 2 encompasses a drilling program focused on transitioning from vertical to horizontal wells, allowing the company to increase production rates and tap into additional reserves. Following several production setbacks caused by adverse weather conditions, the company has achieved peak rates of 770+ barrels of oil equivalent per day (boe/d), with an additional 350 boe/d positioned for optimization.

The company recently revealed promising results from its restructuring efforts in a financial update (https://ibn.fm/MT0Er). Highlights include a Q/Q rise in operating income from $783,084 in 2022 to $1,101,827 in 2023. The company also reported a net income of $71,011 in Q3 2023 – a substantial turnaround from a net loss of $779,438 in Q2 2023. Further, the company announced it raised C$580,000 through the first closing of a private placement debt financing with an equity bonus. Funds from the closing are targeted for drilling, completion, tie-in, well abandonment and reclamation costs, and ongoing ESG initiatives.

“Next summer we got a huge reclamation program to turn all of this back to farming lands, reducing the environmental footprint,” continued Mr. David. “That will also reduce a tremendous amount to the bottom line and opex (operating expenses).”

Samuel David leads Prospera Energy with over 32 years of development and management experience in the oil and gas sectors. Joining him is a diverse team of industry veterans leveraging business development and finance expertise to strategically optimize the company for sustainable growth and profitability.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF

• Canada-based strategic metals innovator Ucore Rare Metals Inc. recently received word that the Canadian government will provide $4.28 million in non-dilutive, non-repayable funding to the company’s ongoing rare earth element (“REE”) separation technology development
• REEs are critical to the production of permanent magnets used in computerized technologies ranging from cell phones to national interests such as renewable energy infrastructure and military defense machinery
• China currently dominates the global market for mining, processing, and product creation for REEs, which underscores Western governments’ interests in developing an independent supply chain for REEs
• Canada’s award will help fund demonstration of Ucore’s RapidSX(TM) capabilities in head-to-head comparisons with the industry-standard CSX separation process for light REEs
• A similar $4 million award from the U.S. government is supporting the demonstration of RapidSX(TM) capabilities for separating heavy REEs, leading up to construction of a commercial facility for separating REEs in Louisiana

A modern-day type of “arms race” focused on computer magnet technology instead of military weaponry is leading Western governments to work with private companies on the development of their own supply chains for the magnets’ components.

Strategic metals innovator Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is celebrating news that the Canadian government will add more than $4 million in non-repayable, non-dilutive funding to a $4 million award the company received from the U.S. government during the summer to demonstrate the effectiveness of Ucore’s trademarked rare earth separation technology.

The $4.28 million award from Canada will help Ucore showcase the capability of its RapidSX(TM) solution for separating light rare earth elements (“REEs”) — specifically praseodymium (Pr), neodymium (Nd), and a praseodymium|neodymium compound (NdPr) — while the U.S. grant is focused on heavy REE magnet materials terbium (Tb) and dysprosium (Dy), according to the Nov. 20 news release (https://ibn.fm/22sfX).

REEs are critical to the makeup of permanent magnets, which are used throughout the infrastructure of renewable energy — in wind turbines and electric vehicle motors, for example. They also are used in military applications such as missile guidance systems, and Ucore Chairman-CEO Pat Ryan recently noted that 920 pounds of rare earths are used in an F-35 fighter.

“China’s recent announcements of increased scrutiny over the export of rare earth elements have raised concerns regarding the ongoing availability of these critical materials. The development of an alternative North American rare earth supply chain is more important than ever as the world moves toward the electrification of its vehicle fleet and other green initiatives,” Ryan stated in the November news release.

That’s in large part because The People’s Republic of China controls the varied aspects of rare earth extraction, production and use in computerized products.

“The challenge is that 60 percent of rare earth resources are in China, but 87 percent of separation to the  ‘critical seeds of technology’, as the Japanese call them — they are controlled by China,” Ryan said during Red Cloud Financial Services’ Fall Mining Showcase this month in Toronto (https://ibn.fm/RGxrl). “That means they’re reaching outside of China now and bringing material back into China for processing, and turning them into final products. And the final products — the rare earth permanent magnets — they’re 90 percent-plus of the global market. So they’ve really got a tight grip.”

Ucore aims to use RapidSX(TM) as a linchpin for re-establishing an REE supply chain in the Americas. The demonstration projects are taking place in Ontario and will lead to the use of RapidSX(TM) commercially once construction is completed at a processing plant — named a Strategic Metals Complex (“SMC”) — in Louisiana. Commissioning is expected at the end of next year there, with it becoming operational in early 2025.

The U.S. government’s funding award includes an additional $10 million to help launch the Louisiana operation, along with $15 million in incentives provided by Louisiana’s state government, according to Ryan.

“We made a number of trips to the White House, to the Pentagon, we talked about our tech,” Ryan said at the Toronto event. “We met with science people and they love what we’re doing.”

The company expects to build a second SMC commercial plant in Canada after completing startup work at the facility in Louisiana, and its long-term outlook includes potential development of an REE mining project in Alaska where the company owns a 100 percent interest in the site.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• In November 2023, Vision Marine filed with the SEC to sell 370,000 ordinary shares priced at $4.05 in a private placement
• The company in November 2023 reported its receipt of a purchase order from boat manufacturer Wired Pontoons for 25 units of its E-Motion 180E powertrain system
• Vision Marine announced in October 2023 delivery of E-Motion 180E powertrain technology to boat manufacturer Groupe Beneteau, to be integrated on the Four Winns H2e Bowrider model
• In August 2023, a catamaran powered by a Vision Marine powertrain set an electric boat world speed record of 116 mph at the Lake of the Ozarks Shootout in Missouri
• The company raised $27 million in a December 2020 U.S. initial public offering

Vision Marine Technologies (NASDAQ: VMAR) is a global leader and innovator within the performance electric recreational boating industry. The company is engaged in designing and manufacturing electric outboard powertrain systems and related technology. It strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment.

Vision Marine manufactures hand-crafted, highly durable, low maintenance, environmentally friendly electric recreational powerboats. The company’s business segments include the sale and rental of electric boats, with the majority of its revenue attributable to electric boat sales.

The designs and technology applied to Vision Marine’s boats result in enhanced performance, higher speeds and longer range. Put simply, Vision Marine boats offer a smoother ride than a traditional internal combustion engine motorboat.

The company is headquartered in Montreal.

Products

Vision Marine’s flagship E-Motion(TM) 180E electric marine powertrain is the first fully electric outboard powertrain combining advanced battery pack, inverter and high efficiency motor with proprietary union assembly between the transmission and motor. Vision Marine’s E-Motion and related technologies in this system utilize extensive control software and are uniquely designed to improve the efficiency of the outboard powertrain. As a result, both range and performance are enhanced.

More than a powerful electric outboard motor, the 180E is a complete powertrain package. The high-tech, marine-specific motor is equipped with multi-sensor captors and independent cooling, providing 180 horsepower.

An onboard charging system allows for quick and easy charging from any shore outlet, whether the vessel is in or out of the water. It implements cutting-edge marine battery packs that are IP67 certified and built to withstand the harshest marine environments. The system is glycol cooled with a controlled heat exchanger, ensuring optimal performance and longevity. A stainless-steel casing protects the battery from corrosion and physical damage over time.

The 180E is built to be integrated with many boat models produced by other marine manufacturers. Since boat manufacturers rarely build their own engines, instead choosing to source them from engine manufacturers, Vision Marine believes the 180E propulsion system can in the future end up powering nearly every recreational boat.

Market Opportunity

According to a report from Future Market Insights, a certified market research organization, the global electric boats market is expected to grow from a value of $5.6 billion in 2023 to $15.1 billion by 2033, achieving a CAGR of 10.4% during the forecast period.

Factors driving growth include rising seaborne commerce activities, a flourishing marine tourism industry and stringent emissions regulations aimed at reducing pollution. In addition, government support for electric speedboat adoption, advances in technological development and research and forecast expansion of needed charging infrastructure are credited as growth drivers.

An emphasis on reducing carbon emissions and encouraging consumer adoption of eco-friendly boats is also likely to drive expansion of the market, the report states.

Management Team

Alexandre Mongeon is Co-Founder and CEO of Vision Marine Technologies. He has served as CEO since 2014. Prior to that, he imported high-performance boats from the United States to Canada for more than 15 years. During much of that time, he also worked as a designer and contractor and managed several new construction projects on the waterfront in and around Montreal. He is a graduate of the School of Construction in Laval, Quebec, with a specialization in electrical systems.

Xavier Montagne is Chief Technical Officer at Vision Marine. Prior to joining the company, he was the CEO of Mac Engineering for six years. While there, he was the electric powerline architect of the Renault Trezor concept car (awarded 2016 Best Concept Car), technical designer of the Zoe E-sport race car driven in Formula-E races from 2016-2019 and senior battery designer for Forsee Power, SAFT, Renault and Peugeot in Europe, to mention a few of the many projects he headed. He received an electronic engineer diploma from IFITEP Paris Polytech in France.

Kulwant Sandher is CFO at Vision Marine. He is a Chartered Professional Accountant with more than 25 years of experience in business and finance. He has served as CFO of multiple public and private companies, including ElectraMeccanica Vehicles Corp., MineSense Technologies Inc., Alba Mineral Ltd., Delta Oil & Gas, Astorius Resources Ltd., Norsemont Mining Inc. and Intigold Mines Ltd. He graduated from Queen Mary College, University of London.

For more information, visit the company’s website at https://VisionMarineTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to VMAR are available in the company’s newsroom at https://ibn.fm/VMAR

• Lexaria, a global innovator in drug delivery platforms, has, through its patented DehydraTECH(TM) technology, proven to enhance the performance of several categories of fat-soluble active molecules and drugs
• Since 2018, human clinical studies on the technology have yielded positive results, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world
• With the strides made so far, Lexaria looks to grow its revenue and commercial opportunities through licensing

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains committed to its mission to provide healthier delivery methods of drugs and other Active Pharmaceutical Ingredients (“APIs”). This is made possible through its patented drug delivery technology, DehydraTECH(TM), proven to enhance the performance of several categories of fat-soluble active molecules and drugs across oral and/or topical product formats.

The company’s efforts have focused on several key segments, including hypertension, diabetes, antivirals, epilepsy, nicotine replacement, and more. This has been an ongoing process since 2016, with positive results achieved from various clinical studies thus far, showing up to 17x brain absorption improvements for oral administration of APIs. In 2021, for instance, the nicotine oral mucosal animal absorption study, NIC-A21-1, demonstrated a 10x to 20x reduction in time to deliver peak levels of nicotine, as well as a 1.7x to 6.6x improvement in nicotine levels in the bloodstream (https://ibn.fm/HrpZL).

This is enabled by DehydraTECH’s specific design for formulating and delivering lipophilic drugs and APIs. By increasing their effectiveness and improving the way they enter the bloodstream, DehydraTECH can offer a wide range of benefits, such as a significant increase in bioavailability, increased brain absorption, improving the speed of onset, masking unwanted tastes, and reduced drug administration costs.

Human clinical studies have been conducted since 2018, with more on the way, ultimately earning Lexaria 37 granted patents globally, with many more pending around the world. From 2018 to 2022, four human clinical studies on the potential treatment of hypertension were completed, evidencing lower blood pressure (“BP”) with zero serious adverse events. Lexaria is now closer than ever to submitting its Investigational New Drug (“IND”) application for its planned U.S. Phase 1b Hypertension Clinical Trial with the U.S. Food and Drug Administration.

For the first half of the 2023 calendar year, animal studies on using DehydraTECH-processed CBD for potentially treating diabetes demonstrated positive results such as reduced triglyceride levels, weight loss, and improved cholesterol levels. . .

“This is a remarkable achievement that speaks to the capabilities of the DehydraTECH technology and also to the Lexaria R&D team, working ardently with scarce resources relative to global multi-billion-dollar behemoths,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/D0s8F).

With the strides made, Lexaria looks to grow its revenue and commercial opportunities through licensing. Given its versatile application areas, the technology can be licensed by both the consumer-packaged goods industry and the drug and pharmaceutical sector. Its suitability cuts across a growing range of consumer product formats, such as registered drugs, nutraceuticals, oral suspensions, topical applications, capsules, pills, tablets and more.

The progress achieved thus far by Lexaria is remarkable. Its goals are also much more significant, as evidenced by the time and resources invested into DehydraTECH development. The efforts so far affirm the company’s commitment to providing healthier delivery methods for drugs and other APIs. They also assert its commitment to creating shareholder value and stamping its position as a leader in its segment.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX